Moreover, based on the finding that TOX expression was negatively correlated with the effects of PD-1 immunotherapy [40], it has been speculated that combined anti-TOX or anti-TOX2 and immune checkpoint inhibitor therapy may be a new approach for tumor immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.